Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intervention of Ovarian Cancer Based on Engineered Immune Effectors (EIEs)
NCT03362606Phase 2Terminated
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in ovarian cancer, sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoint: Safety of OC-CTLs at 6 months. Started Jun 2026; status: terminated.
02
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03362606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03362606.